AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Adagio Medical Holdings, Inc.

$0.45 -$0.63 (-58.29%)
NASDAQ · 14 Sep 2026 20:00 UTC
Previous Close
$0.56
Day Range
$0.45$0.6
Year Range
$0.36$2.58
Market Cap
10.01M
AVG Volume
90.87K
Trailing/Forward PE
-0.32/-
PEG ratio
-0.05
Dividend Yield
-
Next Earnings Date
2026-11-11
Primary Exchange
NASDAQUS
Revenue (USD) · TTM
-200K0200K400K600K24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ADGM Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
26 Q20
26 Q10
25 Q40
25 Q3-143K
25 Q242K
25 Q1296K
24 Q4322K
24 Q3543K
24 Q2399K
24 Q1266K
Net Income (USD) · TTM
-80M-60M-40M-20M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ADGM Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q2-27.14M
26 Q1-24.37M
25 Q4-25.08M
25 Q3-74.58M
25 Q2-69.09M
25 Q1-70.88M
24 Q4-71.18M
24 Q3-27.52M
24 Q2-33.66M
24 Q1-36.47M
Operating Income (USD) · TTM
-80M-60M-40M-20M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ADGM Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q2-19.82M
26 Q1-19.61M
25 Q4-21.8M
25 Q3-68.62M
25 Q2-73.53M
25 Q1-75.47M
24 Q4-76.89M
24 Q3-31.44M
24 Q2-29.89M
24 Q1-30.1M
EBITDA (USD) · TTM
-80M-60M-40M-20M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ADGM EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q2-23.19M
26 Q1-20.43M
25 Q4-21.21M
25 Q3-75.19M
25 Q2-69.64M
25 Q1-71.41M
24 Q4-71.56M
24 Q3-23.72M
24 Q2-30.26M
24 Q1-32.28M
Cash Flows (USD) · TTM
-40M-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ADGM Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q2-16.2M
26 Q1-15.6M
25 Q4-19.01M
25 Q3-23.55M
25 Q2-29.3M
25 Q1-31.75M
24 Q4-31.11M
24 Q3-30.41M
24 Q2-27.65M
24 Q1-26.43M
EPS (USD) · TTM
-6-4-2024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ADGM EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q2-1.43
26 Q1-1.48
25 Q4-1.67
25 Q3-5.06
25 Q2-4.72
25 Q1-4.46
24 Q4-3.99
24 Q3-0.72
24 Q2-1.2
24 Q1-1.06
Expenses (USD) · TTM
-10M010M20M30M40MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ADGM Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q219.4M
26 Q118.84M
25 Q421.12M
25 Q324.99M
25 Q229.63M
25 Q131.65M
24 Q432.63M
24 Q330.82M
24 Q228.95M
24 Q127.17M
Shares Outstanding (USD) · TTM
-600K-400K-200K0200KBuybacks (Repurchases)Stock-Based Compensation24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
ADGM Shares Outstanding (USD) · TTM by quarter
PeriodShares Outstanding (USD) · TTM
26 Q2-416K
26 Q1-171K
25 Q40
25 Q3-589K
25 Q2-452K
25 Q1-329K
24 Q4-221K
24 Q3-334K
24 Q2-453K
24 Q1-342K
Employee Count
02040608020242025
ADGM Employee Count by quarter
PeriodEmployee Count
202541
202471
Free Cash Flow Yield
-300%-200%-100%0%med -145.76%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
ADGM Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-161.87%
Sep 26-129.98%
Sep 26-129.29%
Aug 26-142.7%
Aug 26-112.34%
Aug 26-105.35%
Aug 26-102.73%
Jul 26-185.62%
Jul 26-145.68%
Jul 26-132.49%
Jul 26-123.19%
Jul 26-110.25%
Jun 26-108.73%
Jun 26-103.26%
Jun 26-94.25%
Jun 26-96.85%
May 26-96.99%
May 26-83.49%
May 26-81.61%
May 26-96.81%
May 26-91.64%
Apr 26-62.51%
Apr 26-60.9%
Apr 26-73.74%
Apr 26-75.51%
Mar 26-77.37%
Mar 26-135.51%
Mar 26-145.84%
Mar 26-156.74%
Feb 26-153.13%
Feb 26-155.46%
Feb 26-155.46%
Feb 26-154.68%
Jan 26-153.13%
Jan 26-141.79%
Jan 26-168.28%
Jan 26-157.83%
Jan 26-141.79%
Dec 25-147.24%
Dec 25-148.67%
Dec 25-156.1%
Dec 25-165.37%
Nov 25-190.91%
Nov 25-193.84%
Nov 25-195.15%
Nov 25-209.27%
Oct 25-167.08%
Oct 25-144.3%
Oct 25-138.03%
Oct 25-94.29%
Oct 25-95.24%
Sep 25-99.73%
Sep 25-111.39%
Sep 25-110.74%
Sep 25-120.55%
Aug 25-118.31%
Aug 25-147.65%
Aug 25-148.81%
Aug 25-152.97%
Aug 25-163.9%
Jul 25-120.06%
Jul 25-147.51%
Jul 25-122.2%
Jul 25-133.23%
Jun 25-162.61%
Jun 25-187.74%
Jun 25-189.46%
Jun 25-162.61%
May 25-182.75%
May 25-173.54%
May 25-175.01%
May 25-143.31%
May 25-166.06%
Apr 25-160.91%
Apr 25-117.52%
Apr 25-272.8%
Apr 25-282.41%
Mar 25-222.56%
Mar 25-241.83%
Mar 25-193.69%
Mar 25-197.34%
Feb 25-251.24%
Feb 25-149.42%
Feb 25-162.16%
Feb 25-181.9%
Jan 25-178.79%
Jan 25-207.11%
Jan 25-270.09%
Jan 25-219.52%
Jan 25-186.77%
Dec 24-199.22%
Dec 24-126.78%
Dec 24-103.56%
Dec 24-90.95%
Nov 24-78.35%
Nov 24-84.69%
Nov 24-69.73%
Nov 24-143.81%
Nov 24-132.71%
Oct 24-124.47%
Price to Sales
-2500250500750med 54.62Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26
ADGM Price to Sales by quarter
PeriodPrice to Sales
Mar 26-121.55
Mar 26-112.94
Mar 26-105.09
Feb 26-107.56
Feb 26-105.95
Feb 26-105.95
Feb 26-106.49
Jan 26-107.56
Jan 26-116.17
Jan 26-97.88
Jan 26-104.36
Jan 26-116.17
Dec 25-111.87
Dec 25-110.79
Dec 25-105.52
Dec 25-99.6
Nov 25-86.28
Nov 25-84.98
Nov 25-84.4
Nov 25333.34
Oct 25417.5
Oct 25483.42
Oct 25505.39
Oct 25739.78
Oct 25732.46
Sep 25699.49
Sep 25626.25
Sep 25629.91
Sep 25578.64
Aug 25589.63
Aug 25472.43
Aug 25468.77
Aug 2570.12
Aug 2565.45
Jul 2589.34
Jul 2572.72
Jul 2587.79
Jul 2580.51
Jun 2565.97
Jun 2557.14
Jun 2556.62
Jun 2565.97
May 2558.7
May 2561.81
May 2561.29
May 2567.41
May 2558.17
Apr 2534.8
Apr 2547.65
Apr 2520.53
Apr 2519.83
Mar 2525.16
Mar 2523.15
Mar 2528.91
Mar 2528.37
Feb 2522.29
Feb 2537.48
Feb 2534.53
Feb 2530.78
Jan 2531.32
Jan 2527.04
Jan 2520.73
Jan 2525.51
Jan 2529.98
Dec 2428.11
Dec 2444.17
Dec 2454.07
Dec 2461.57
Nov 2471.47
Nov 2466.12
Nov 2480.3
Nov 2448.18
Nov 2452.22
Oct 2455.67
Oct 2453.75
Oct 2454.33
Oct 2455.48
Sep 2454.9
Sep 2473.91
Sep 2478.32
Sep 2483.51
Aug 2498.86
Aug 24152.17
Aug 24158.61
Aug 24169.73
Aug 24239.08
Price to Book
01234med 1.6Dec 24Mar 25May 25Aug 25Oct 25May 26Aug 26
ADGM Price to Book by quarter
PeriodPrice to Book
Aug 262.65
Jul 261.47
Jul 261.87
Jul 262.06
Jul 262.21
Jul 262.47
Jun 262.51
Jun 262.64
Jun 262.89
Jun 262.81
May 262.81
May 263.26
May 263.34
May 261.58
May 261.67
Apr 262.45
Apr 262.52
Apr 262.08
Apr 262.03
Mar 261.98
Nov 251.62
Oct 252.02
Oct 252.34
Oct 252.45
Oct 253.59
Oct 253.55
Sep 253.39
Sep 253.04
Sep 253.05
Sep 252.8
Aug 252.86
Aug 252.29
Aug 252.27
Aug 251.67
Aug 251.56
Jul 252.13
Jul 251.74
Jul 252.1
Jul 251.92
Jun 251.57
Jun 251.36
Jun 251.35
Jun 251.57
May 251.4
May 251.48
May 251.46
May 251.09
May 250.94
Apr 250.25
Apr 250.34
Apr 250.15
Apr 250.14
Mar 250.18
Mar 250.16
Mar 250.21
Mar 250.2
Feb 250.16
Feb 250.27
Feb 250.24
Feb 250.22
Jan 250.22
Jan 250.19
Jan 250.15
Jan 250.18
Jan 250.21
Dec 240.2
Dec 240.31
Dec 240.38
Dec 240.44
Nov 240.51
Nov 240.47
Nov 240.57
Adagio Medical Holdings, Inc.
ADGM
Stockpicker

Video analysis: ADGM

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: ADGM

Adagio Medical Reports Second Quarter 2026 Results

businesswire.com · 11 Aug 2026

Adagio Medical Reports Second Quarter 2026 Results

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #ARRHYTHMIA--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2026. Recent Business Highlights: Announced the successful treatment at the Hospital of University of Pennsylvania of the first patient with the Company's next-generation vCLAS™ Ultra Ultra-Low temperature ablation cat.

Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System

businesswire.com · 3 Aug 2026

Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $ADGM #ARRHYTHMIA--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the successful treatment of the first patient with its next-generation vCLAS Ultra Ultra-Low Temperature Ablation (“ULTA”) system under Expanded Access authorization from the U.S. Food and Drug Administration (“FDA”).The patient, who presented with non-ischemic cardiomyopath.

Robo.ai Announces Core Executive Appointments, Forming a Local UAE Leadership Team at Neurovia AI

gurufocus.com · 14 Jul 2026

Robo.ai Announces Core Executive Appointments, Forming a Local UAE Leadership Team at Neurovia AI

Robo.ai Announces Core Executive Appointments, Forming a Local UAE Leadership Team at Neurovia AI PR Newswire AB

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.